Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry
Background: Ibrutinib is widely known as an effective and well-tolerated therapeutical choice of the chronic lymphocytic leukaemia (CLL). However, acquired resistance may occur during the treatment, causing relapse. Early detection of ibrutinib resistance is an important issue, therefore we aimed to...
Main Authors: | Ferenc Takács, Lili Kotmayer, Ágnes Czeti, Gábor Szalóki, Tamás László, Gábor Mikala, Ágnes Márk, András Masszi, Péter Farkas, Márk Plander, Júlia Weisinger, Judit Demeter, Sándor Fekete, László Szerafin, Beáta Margit Deák, Erika Szaleczky, Adrienn Sulák, Zita Borbényi, Gábor Barna |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Pathology and Oncology Research |
Subjects: | |
Online Access: | https://www.por-journal.com/articles/10.3389/pore.2022.1610659/full |
Similar Items
-
Ibrutinib response in a patient with refractory mixed essential cryoglobulinemia
by: Haya Jamali, et al.
Published: (2023-05-01) -
Ibrutinib-Induced Skin Rash
by: Sudhir Kirar, et al.
Published: (2021-02-01) -
Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
by: Nurhilal Büyükkurt, et al.
Published: (2023-06-01) -
Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia
by: Ayşe Kaya, et al.
Published: (2024-03-01) -
İbrutinib Sonrası Gelişen Dev Ekimoz ve Hematom: Olgu Sunumu
by: Aynur Uğur Bilgin, et al.
Published: (2017-03-01)